--- title: "Cardiology Clinical Research Feed | MedicHelpline" specialty: "Cardiology" specialty_slug: "cardiology" canonical_url: "https://medichelpline.com/clinical-feed/cardiology" content_type: "clinical_feed_specialty" page: 1 articles_in_batch: 30 generated_at: "2026-09-05T23:52:18.974Z" license: "CC-BY-NC-4.0 / Informational Use" --- # Cardiology — Clinical Research Feed ## Specialty Overview: Cardiology Latest peer-reviewed clinical trials, guidelines, and observational research in **Cardiology**, indexed and structured for clinical intelligence and AI reasoning. ## Latest Cardiology Publications ### 1. [Kylo-11 phase 1 trial: safety and durable reduction of lipoprotein(a) after single subcutaneous do](https://medichelpline.com/clinical-feed/pubmed-42664979.md) - **Source:** PubMed / NCBI | **Published:** 2026-09-05 | DOI: [10.1016/S0140-6736(26)01484-4](https://doi.org/10.1016%2FS0140-6736(26)01484-4) - **Detail Markdown URL:** [Kylo-11 phase 1 trial: safety and durable reduction of lipoprotein(a) after single subcutaneous do](https://medichelpline.com/clinical-feed/pubmed-42664979.md) > **Executive GIST:** - This first-in-human, randomised, double-blind, placebo-controlled phase 1 trial evaluated **Kylo-11**, a non-canonical, long-duration small interfering RNA designed to lower **lipoprotein(a)**, in otherwise healthy adults with elevated Lp(a). - The study enrolled adults aged 18–55 at a single hospital site in China and randomized participants 8:2 to receive a single subcutaneous dose of Kylo-11 or placebo across seven dosing cohorts. - Dosing cohorts included 9, 30, 75, 225, 450, and 600 mg for participants with baseline Lp(a) 75–200 nmol/L; an additional cohort (cohort 7) gave 225 mg to participants with baseline Lp(a) >200 nmol/L. - Primary endpoint was incidence of investigator-assessed adverse events within 24 weeks; safety analysis included all dosed participants; pharmacodynamic analysis included those with at least one post-dose PD datapoint. - 71 participants were randomised between May 30 and Dec 30, 2024; 70 received study drug (57 Kylo-11, 14 placebo). Median age 27.5 years; 65% male. Median follow-up was 337 days. - Adverse events up to 24 weeks occurred in 53% (37/70) and were mostly grade 1–2 and judged unrelated to study drug. There were no injection-site reactions, no drug-related adverse events, no serious adverse events, and no deaths. - Three grade ≥3 events were adjudicated unrelated to Kylo-11: two in Kylo-11 225 mg cohort (transient hypertriglyceridaemia and elevated creatine phosphokinase on day 168) and one in placebo (transient hypertriglyceridaemia on day 84). - Pharmacodynamic results at 48 weeks showed dose-dependent median percent reductions in serum Lp(a): from –53% at 9 mg up to –97% at 600 mg; absolute median reductions ranged from –71 nmol/L (9 mg) to –129 nmol/L (600 mg). - In cohort 7 (225 mg with baseline Lp(a)>200 nmol/L) median reduction at 48 weeks was –96% (–208 nmol/L), indicating substantial absolute and relative reductions in very high baseline Lp(a). - Interpretation: a single subcutaneous dose of Kylo-11 was well tolerated and produced durable reductions in serum Lp(a) for up to 48 weeks at doses ≥225 mg. Funding was provided by Kylonova Biopharma. - Conflict of interest disclosures: several authors are employees or inventors with Hygieia Pharmaceuticals or Kylonova; some authors have roles in other Lp(a) trials or industry relationships; other authors declared no competing interests. ### 2. [Intensive blood pressure control linked to 15% lower 7-year dementia risk](https://medichelpline.com/clinical-feed/medical-news-today-0-intensive-blood-pressure-control-cuts-7-year-dementia-risk-by-15-study-finds.md) - **Source:** Medical News Today | **Published:** 2026-09-04 - **Detail Markdown URL:** [Intensive blood pressure control linked to 15% lower 7-year dementia risk](https://medichelpline.com/clinical-feed/medical-news-today-0-intensive-blood-pressure-control-cuts-7-year-dementia-risk-by-15-study-finds.md) > **Executive GIST:** - Past research links **cardiovascular disease** and specific cardiac conditions to higher dementia risk; **hypertension** is among those risk factors. - A new study presented at the European Society of Cardiology (ESC) Congress 2026 evaluated community-based blood pressure interventions and dementia outcomes. - The analysis used data from the **China Rural Hypertension Control Program (CRHCP)** where 326 rural villages were randomized to receive either a non-physician community healthcare provider-led intervention or usual care. - Nearly 34,000 adults aged 40 and older participated; the mean age was 63 years. - The study report asserts that more intensive blood pressure lowering was associated with a **15%** reduction in dementia risk over seven years. - The source article does not provide full details on the intervention protocol, blood pressure targets, exact baseline blood pressure ranges, statistical methods, absolute risk reductions, confidence intervals, or adverse events; those details were not reported in the source. - Because the published summary is limited, interpretation should note that the report is based on a conference presentation and that granular methodological and outcome data are needed to assess generalizability and clinical implementation. - The findings support the hypothesis that blood pressure control may reduce long-term **dementia** risk, but clinicians should await full study details before changing practice recommendations. ### 3. [My Health is Our Health: AHA and Ascension Seton launch Austin campaign on pregnancy and heart hea](https://medichelpline.com/clinical-feed/aha-news-0-american-heart-association-and-ascension-seton-launch-initiative-to-help-austin.md) - **Source:** AHA News (American Heart Association) | **Published:** 2026-09-04 - **Detail Markdown URL:** [My Health is Our Health: AHA and Ascension Seton launch Austin campaign on pregnancy and heart hea](https://medichelpline.com/clinical-feed/aha-news-0-american-heart-association-and-ascension-seton-launch-initiative-to-help-austin.md) > **Executive GIST:** - The American Heart Association launched the **My Health is Our Health** campaign in Austin as part of its **Go Red for Women** movement to raise awareness of the link between **pregnancy** and **cardiovascular disease**. - The initiative is supported locally by **Ascension Seton**, which is contributing clinical and educational support to help pregnant women and new mothers understand cardiovascular risk. - Pregnancy functions as a natural “stress test,” often revealing conditions such as **high blood pressure** and **gestational diabetes** that signal elevated future heart disease risk. - Adverse pregnancy outcomes cited include **preeclampsia**, gestational diabetes, and fetal growth restriction; these can increase lifetime risk of heart disease, heart failure and stroke for mothers and predispose children to metabolic and cardiac issues. - The United States has the highest maternal mortality rates among developed countries; pregnancy-related deaths have risen substantially over recent decades, and many pregnancy-associated deaths are avoidable. - The campaign emphasizes awareness, education and early management of cardiovascular risk during and after pregnancy to improve short- and long-term outcomes for mothers and children. - Ascension Seton frames the effort as part of its commitment to improving maternal health outcomes and enabling women to access information and care during pregnancy and beyond. - The release includes statements from Dr. Jeny Ghartey, Maternal Fetal Medicine specialist and Chief of Obstetrics and Gynecology at Ascension Seton, and Derek Curlee, Vice President of Women's Services at Ascension Seton, highlighting the importance of prioritizing heart health in maternity care. - The American Heart Association directs readers to its Go Red for Women pregnancy resources for more information on cardiovascular disease in pregnancy. - Media and public contact information for the American Heart Association is provided in the source for follow-up inquiries. ### 4. [AHA and NFL PLAY 60 grant awards support physical activity at two Eastern Washington schools](https://medichelpline.com/clinical-feed/aha-news-1-two-eastern-washington-schools-awarded-grants-to-improve-student-health.md) - **Source:** AHA News (American Heart Association) | **Published:** 2026-09-04 - **Detail Markdown URL:** [AHA and NFL PLAY 60 grant awards support physical activity at two Eastern Washington schools](https://medichelpline.com/clinical-feed/aha-news-1-two-eastern-washington-schools-awarded-grants-to-improve-student-health.md) > **Executive GIST:** - The American Heart Association (AHA) and the National Football League (NFL) awarded two $500 **NFL PLAY 60** grants to Eastern Washington elementary schools through the AHA’s school programs, Kids Heart Challenge and American Heart Challenge. - Lind Elementary in Lind, Wash., received an **NFL PLAY 60 Active Recess Grant** to buy equipment and enhance recess activity options. - Herian Elementary in Cusick, Wash., received an **NFL PLAY 60 Flag Football Equipment Grant** to expand access to flag football and support student engagement and confidence. - The grants are part of an annual $350,000 funding pool provided by the NFL via NFL PLAY 60 to support school-identified needs such as recess enhancements, equipment, inclusive PE and FLAG football. - The AHA highlights that about **1 in 5 children** in the U.S. live with obesity and that a similar proportion meet the recommended 60 minutes of daily physical activity; the grants aim to increase opportunities for youth to be active. - Educators at both schools noted the grants will introduce new activities, expand programming in a rural setting, and help students become more active and confident. - NFL PLAY 60 encourages at least 60 minutes of vigorous daily activity and ties into the U.S. Department of Health and Human Services’ Physical Activity Guidelines for Americans. - The initiative also leverages NFL mascot ambassadors to inspire movement; the current ambassador class is listed in the source. - Grant applications are accepted year-round; more information is available at heart.org/jointhechallenge. Contact details for media and public inquiries were provided in the source. ### 5. [Field-of-view confounding in self-supervised cardiac imaging alters genetic discovery](https://medichelpline.com/clinical-feed/medrxiv-9-field-of-view-confounding-shapes-genetic-discovery-from-self-supervised-cardiac.md) - **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-09-04 - **Detail Markdown URL:** [Field-of-view confounding in self-supervised cardiac imaging alters genetic discovery](https://medichelpline.com/clinical-feed/medrxiv-9-field-of-view-confounding-shapes-genetic-discovery-from-self-supervised-cardiac.md) > **Executive GIST:** - Self-supervised models can convert medical images into quantitative phenotypes for genetic discovery, but statistical reproducibility alone does not ensure the phenotype represents the intended anatomy. - A video masked-autoencoder was trained on **69,932 UK Biobank cardiac cine-MRI** studies and its latent representation was subjected to genome-wide association analysis. - Of the top 20 latent axes, **18 of 20** were heritable and produced well-calibrated association statistics, yet encoded substantial non-cardiac information related to **field-of-view**, including body size, stature and imaging centre (linear-probe R² = **0.55** for site). - Standard genomic-control and LD-score diagnostics failed to detect this phenotype-level confounding originating from image acquisition and body habitus. - Restricting the image **field of view** to the heart and residualising body and acquisition covariates before dimensionality reduction reduced both linear and non-linear nuisance signals while preserving cardiac information. - Residualising only at the association-testing stage attenuated some nuisance associations but recovered less cardiac-associated genetic signal, indicating nuisance variation had already shaped the learned principal-component basis. - The corrected representation identified novel genetic loci beyond those found with supervised phenotypes at the same sample size; these loci shared genetic architecture with cardiac-conduction traits and localized to cardiac structures inside the imaged field of view. - The study demonstrates that confounding in learned medical-image phenotypes can arise upstream of association testing and highlights the need to audit and, when appropriate, correct learned representations prior to genetic analysis. - Data availability: individual-level UK Biobank data accessible under application 65439; external GWAS and eQTL resources used are publicly available; aggregate per-axis summary statistics available from corresponding author on request. - Ethical oversight: UK Biobank approved, participant informed consent obtained; research under UK Biobank application 65439; authors declare no competing interests. ### 6. [Bayesian Network Meta-Analysis of P2Y12 Inhibitors After ACS: Efficacy, Bleeding, and Uncertainty](https://medichelpline.com/clinical-feed/medrxiv-2-what-additional-insights-does-a-bayesian-network-meta-analysis-provide.md) - **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-09-04 - **Detail Markdown URL:** [Bayesian Network Meta-Analysis of P2Y12 Inhibitors After ACS: Efficacy, Bleeding, and Uncertainty](https://medichelpline.com/clinical-feed/medrxiv-2-what-additional-insights-does-a-bayesian-network-meta-analysis-provide.md) > **Executive GIST:** - The authors updated a prior systematic review and performed a **Bayesian network meta-analysis** (NMA) of P2Y12 inhibitors after acute coronary syndromes (ACS), adding two trials to reach 19 randomized controlled trials (RCTs) with 60,619 patients in total. - Primary efficacy outcome was a composite major adverse cardiovascular events (**MACE**) endpoint: all-cause mortality, recurrent non-fatal myocardial infarction, or non-fatal stroke. Primary safety outcome was study-reported **major bleeding**. - The Bayesian model used a binomial complementary log-log specification with a log(time) offset and random effects; the analysis included prior and posterior predictive checks, convergence diagnostics, model comparisons, and sensitivity analyses. - The authors report probabilities for a range of practical equivalence (ROPE) defined as hazard ratio (HR) 0.90–1.11 to quantify clinically meaningful equivalence versus benefit or harm. - For MACE, prasugrel versus clopidogrel had an estimated HR 0.87 (95% credible interval [CrI] 0.76–1.03) and a 70% posterior probability of clinical efficacy benefit (HR 1.1). Prasugrel versus clopidogrel had HR 1.10 (95% CrI 0.88–1.26) with a 51% probability of meaningful bleeding harm. - The Bayesian framework highlighted clinically important uncertainties and identified probable regions of equivalence among P2Y12 inhibitors that the prior frequentist NMA— which concluded prasugrel provided an optimal efficacy-safety balance—may have underappreciated. - The authors report transparent statistical workflow details and make data and code available online at the provided GitHub repository. - Competing interests: none declared. Ethical statements: only previously published data used; trial registration and reporting guidelines followed as indicated in the source. ### 7. [PGS000936 polygenic risk score stratifies hypercholesterolemia risk in an independent German cohort](https://medichelpline.com/clinical-feed/medrxiv-1-established-polygenic-risk-score-for-hypercholesterinemia-demonstrates.md) - **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-09-04 - **Detail Markdown URL:** [PGS000936 polygenic risk score stratifies hypercholesterolemia risk in an independent German cohort](https://medichelpline.com/clinical-feed/medrxiv-1-established-polygenic-risk-score-for-hypercholesterinemia-demonstrates.md) > **Executive GIST:** - The study evaluated a published hypercholesterolemia **polygenic risk score (PGS000936)** comprising 5,386 genome-wide loci in an independent German sample. - Genotypes from 117 monogenic-negative hypercholesterolemia cases and 496 population controls (Illumina GSA v3.0, imputed to ~11 million variants) were used; the score was applied without retraining using external β-coefficients. - The PRS strongly discriminated cases from controls (p < 2×10-16); mean PRS was 0.97 in cases versus 0.52 in controls. - Individuals in the top 10% of the PRS distribution had a substantially higher odds of hypercholesterolemia (OR 7.55; 95% CI 4.36–13.07; p < 0.0001). - In the subset of 94 cases with available clinical data, higher PRS correlated with higher **LDL-C** concentrations measured before treatment. - The German control cohort’s PRS distribution was shifted relative to the original study’s control cohort, indicating the need for **population-matched calibration** for accurate odds estimation and interpretation of PRS values. - Ethical approval was obtained from the Leipzig University Ethics Committee (approval no. 222 402-16ek); participants provided written informed consent. - Data sources include UK Biobank and the PGS Catalog entry for PGS000936; the study is a medRxiv preprint and has not undergone peer review. - Details not reported in the source: full demographic characteristics of cases/controls, detailed imputation metrics, and reclassification performance metrics beyond reported odds ratios and mean PRS values. ### 8. [Post-MI TRPV1 Cardiac Afferent Ablation with RTX Prevents Arrhythmogenic Remodeling](https://medichelpline.com/clinical-feed/biorxiv-7-trpv1-cardiac-afferent-ablation-after-completed-myocardial-infarction-prevents.md) - **Source:** bioRxiv (Biomedical Preprints) | **Published:** 2026-09-04 - **Detail Markdown URL:** [Post-MI TRPV1 Cardiac Afferent Ablation with RTX Prevents Arrhythmogenic Remodeling](https://medichelpline.com/clinical-feed/biorxiv-7-trpv1-cardiac-afferent-ablation-after-completed-myocardial-infarction-prevents.md) > **Executive GIST:** - The study tested whether targeted ablation of **TRPV1**-expressing cardiac sensory afferents during the subacute period after completed myocardial infarction (MI) reduces later arrhythmogenic remodeling. - Yorkshire pigs underwent anterior MI or sham surgery, then at two weeks post-MI were randomized to percutaneous epicardial administration of resiniferatoxin (**RTX**) for cardiac-selective TRPV1 afferent depletion or to vehicle. Terminal assessments were performed four weeks after treatment. - Ablation of cardiac TRPV1 afferents was confirmed functionally by blunted responses to TRPV1 agonists. RTX-treated animals showed improved left ventricular function and reduced end-diastolic diameter compared with vehicle-treated MI controls. - RTX reduced inducibility of ventricular tachycardia/ventricular fibrillation (**VT/VF**) on in vivo electrophysiologic testing. Endocardial electroanatomic mapping showed fewer deceleration zones and late potentials in RTX-treated hearts. - Epicardial multielectrode mapping demonstrated decreased electrophysiologic heterogeneity in the scar border zone after RTX treatment. - Real-time neurotransmitter sensing during sympathoexcitation indicated normalization of adrenergic mediator release—specifically **noradrenaline** and neuropeptide Y—in RTX-treated animals. - Histologic analysis found attenuated myocardial fibrosis in the scar border zone, reduced sympathetic nerve sprouting, and decreased T cell infiltration in cardiac sensory ganglia after RTX treatment. - Bulk RNA sequencing of stellate ganglia from RTX-treated animals revealed downregulation of adrenergic genes, suggesting altered neuro-cardiac axis signaling. - The authors conclude that cardiac-selective TRPV1 afferent ablation during the subacute post-MI window mitigates structural, electrophysiologic, and neuro-cardiac remodeling and may be a promising therapeutic strategy for reducing post-MI ventricular arrhythmias. - This report is a preprint and not yet peer-reviewed; specific quantitative details (e.g., exact numbers, statistical values) and longer-term follow-up were not reported in the source abstract. ### 9. [Circulating Biomarkers in Cardio‑Oncology: Review of Publication Details and Availability](https://medichelpline.com/clinical-feed/pubmed-42696226.md) - **Source:** PubMed / NCBI | **Published:** 2026-09-04 | DOI: [10.1007/s11886-026-02407-y](https://doi.org/10.1007%2Fs11886-026-02407-y) - **Detail Markdown URL:** [Circulating Biomarkers in Cardio‑Oncology: Review of Publication Details and Availability](https://medichelpline.com/clinical-feed/pubmed-42696226.md) > **Executive GIST:** - Article title: “Circulating Biomarkers in Cardio-Oncology: Prediction and Prognostication.” - Publication: Curr Cardiol Rep; publication date 2026 Sep 4; volume 28(1):88; DOI 10.1007/s11886-026-02407-y; PMID 42696226. - Article type: Review (as indexed on PubMed/NCBI). - Lead and contributing authors: Jean Kim et al.; multiple coauthors listed including Benjamin Lee, Audrey White, Le Huang, Faraaz Azam, Benjamin Yang, Kathleen Zhang, Daniel Addison, Amit Arbune, Vlad G Zaha, Alvin Chandra. - Institutional affiliations: Authors are affiliated with University of Texas Southwestern Medical Center (Division of Cardiology, Department of Internal Medicine, Harold C. Simmons Comprehensive Cancer Center), and Parkland Health, Dallas, TX, USA. - Contact details: Corresponding author email addresses for Jean Kim and Alvin Chandra are shown on the PubMed record. - Content availability: PubMed record displays bibliographic metadata and navigation links; the abstract and full review text were not included in the provided source excerpt. - Access and indexing features: Permalink, DOI link, citation export, and PubMed navigation (Abstract, Title & authors, References, MeSH terms, Substances) are presented on the record. - Limitations: Specific study findings, biomarker names, evidence synthesis, recommendations, data, and conclusions are not reported in the supplied source content and therefore cannot be summarized here. - Usage guidance: For the full review content, readers should follow the DOI or PubMed links to access the journal article; absent details cannot be inferred from the metadata alone. ### 10. [Lifelong Roadmap After Acute Coronary Syndrome: ESC/EAPC Clinical Consensus](https://medichelpline.com/clinical-feed/pubmed-42017832.md) - **Source:** PubMed / NCBI | **Published:** 2026-09-04 | DOI: [10.1093/eurjpc/zwag236](https://doi.org/10.1093%2Feurjpc%2Fzwag236) - **Detail Markdown URL:** [Lifelong Roadmap After Acute Coronary Syndrome: ESC/EAPC Clinical Consensus](https://medichelpline.com/clinical-feed/pubmed-42017832.md) > **Executive GIST:** - This record is a clinical consensus statement titled “Optimal lifelong roadmap post-acute coronary syndrome,” produced by the European Association of Preventive Cardiology (EAPC) of the European Society of Cardiology (ESC). - Publication: European Journal of Preventive Cardiology, 2026 Sep 4;33(11):1913–1939. DOI: 10.1093/eurjpc/zwag236. PubMed PMID: 42017832. The article is listed as a free article. - The statement is authored by a multi‑national group of clinicians and researchers (lead author Roberto F E Pedretti et al.) with affiliations across Europe, including Italy, Belgium, UK, Sweden, Norway, Spain, Switzerland, Greece, Poland and patient representatives from the ESC Patient Forum. - The document is classified as a Review and a clinical consensus statement originating from an ESC association (EAPC), indicating expert synthesis and guidance rather than novel primary trial data. - The title and metadata indicate the focus is on an **optimal lifelong roadmap** for patients after **acute coronary syndrome (ACS)**, and that the scope is preventive cardiology and long‑term care. - The PubMed page lists author affiliations and multiple contributors from cardiology departments, rehabilitation units, research institutes, and patient forums, reflecting multidisciplinary input. - The PubMed entry does not include the article abstract text or the detailed recommendations, pathways, algorithms, or specific interventions from the consensus; those full details are available in the linked full text source (journal site). - Because the PubMed source provided here contains only bibliographic and authorship metadata, specific clinical content, recommendations, risk stratification tools, follow‑up schedules, pharmacologic or nonpharmacologic interventions, and evidence grading are not reported in this source and cannot be reproduced. - For the full consensus guidance, clinical algorithms, and implementation details referenced by the title, clinicians should consult the full text linked via the DOI or the European Journal of Preventive Cardiology platform. - Key searchable identifiers to locate the full statement: article title, DOI 10.1093/eurjpc/zwag236, PubMed PMID 42017832, journal Eur J Prev Cardiol 2026;33(11):1913–1939. - The consensus document likely addresses secondary prevention and lifelong management after ACS given the title and issuing body (EAPC/ESC); however, specific recommendations and evidence cited are not available in the PubMed abstract entry provided here. ### 11. [ESC Quality Indicators for Post-Myocardial Infarction Care: Transition and Chronic Coronary Syndro](https://medichelpline.com/clinical-feed/pubmed-41342498.md) - **Source:** PubMed / NCBI | **Published:** 2026-09-04 | DOI: [10.1093/eurjpc/zwaf761](https://doi.org/10.1093%2Feurjpc%2Fzwaf761) - **Detail Markdown URL:** [ESC Quality Indicators for Post-Myocardial Infarction Care: Transition and Chronic Coronary Syndro](https://medichelpline.com/clinical-feed/pubmed-41342498.md) > **Executive GIST:** - This PubMed entry reports a 2026 Eur J Prev Cardiol article titled **ESC quality indicators for post-myocardial infarction care: transition and chronic coronary syndrome phases**. - Citation details include publication date (2026 Sep 4), journal (Eur J Prev Cardiol), volume 33(11):1940–1949, DOI 10.1093/eurjpc/zwaf761 and PMID 41342498. - The article is listed as a free article on PubMed; full-text links are indicated but the abstract and article body content were not included in the provided source text. - A multi-author, multi-centre author group is listed, with affiliations across European cardiac centres and universities, indicating a collaborative guideline or consensus output. Key author affiliations span Lausanne, Geneva, Leeds, Palma de Mallorca, Barcelona, Bern, Trondheim, Athens, Hasselt, Rome, Cologne, Vienna, Potsdam, Antwerp, Vancouver, and other centres. - The title indicates the paper focuses on **quality indicators** developed or endorsed by the European Society of Cardiology (ESC) for post-**myocardial infarction** care, specifically covering the transitional phase after hospital discharge and the subsequent **chronic coronary syndrome** phase. - The source text does not provide the article abstract, specific indicators, methods, results, recommendations, or performance measures; those details are not reported in the provided PubMed page content. - To review the substantive clinical content (indicator definitions, numerator/denominator specifications, applicability, or implementation guidance), readers must access the full text via the journal or provided full-text links; the PubMed record alone lacks those clinical details. - The record includes DOI and full-text link pointers, enabling retrieval of the complete article for clinical application, audit design, or incorporation into quality-improvement programs. - Conflict-of-interest statements, detailed methodology, evidence grading, and recommended metrics were not visible in the provided source material and therefore cannot be summarized here. ### 12. [New ACC/AHA Guidance on Cardiovascular Care for Tactical Athletes](https://medichelpline.com/clinical-feed/stat-news-1-tactical-athletes-get-new-guidance-for-cardiovascular-fitness.md) - **Source:** STAT News | **Published:** 2026-09-03 - **Detail Markdown URL:** [New ACC/AHA Guidance on Cardiovascular Care for Tactical Athletes](https://medichelpline.com/clinical-feed/stat-news-1-tactical-athletes-get-new-guidance-for-cardiovascular-fitness.md) > **Executive GIST:** - The American College of Cardiology and the American Heart Association released new cardiovascular guidance specifically for **tactical athletes**, defined as military, emergency response, and public safety personnel whose performance affects others’ lives. - The guidance addresses evaluation, risk stratification, and management of tactical athletes with or at risk for **cardiovascular disease**, and was published in JACC and Circulation. - Authors estimate about 4 million Americans serve as tactical athletes across roles such as EMTs, firefighters, police officers, military personnel, and astronauts. - Tactical athletes face distinct occupational demands: sudden transitions from rest to maximal exertion, extreme environments (heat, cold, altitude, deep water), heavy equipment, and acute emotional stress during emergencies. - The top duty-related cause of death in this group is **cardiovascular disease**, with increased event rates during recruit training and at moments of acute alarm for firefighters. - Common cardiovascular risk factors (hypertension, hyperlipidemia, obesity, type 2 diabetes, and smoking) are more prevalent in many tactical populations; one cited dataset found 18% of active-duty service members had at least one major risk factor and 24% were active smokers. - Specific exposures may raise risk in subgroups: for example, spaceflight radiation is hypothesized to accelerate atherosclerosis in astronauts; firefighters with prior cardiovascular disease, hypertension, or smoking history had higher likelihood of fatal cardiovascular events. - Risk changes over a career: fitness and cardiovascular capacity may decline with age, making role reassignment or job modification a reasonable option rather than complete removal from service. - The new guidance differs from competitive-sports guidance on shared decision-making: while competitive athletes were encouraged to use shared decision-making about play, tactical contexts give greater weight to organizational stakeholders because incapacitation can endanger others. - Experts quoted (Benjamin Levine, Lili Barouch, Brian Becerra, Tim Churchill) emphasize the need for tailored assessments, context-based job fitness decisions, and better clinician awareness of tactical demands. - The guidance is intended to help clinicians apply appropriate strategies recognizing both individual rights to care and the broader safety implications of tactical-athlete health. - STAT notes the guidance responds to a gap in care for highly elite professionals serving community safety, and that sports cardiologists have welcomed the framework. ### 13. [Framework for Assessing Cardiovascular Risk and Fitness for Duty in Tactical Athletes](https://medichelpline.com/clinical-feed/aha-news-0-new-guidance-introduces-framework-for-assessing-cardiovascular-risk-and-fitness.md) - **Source:** AHA News (American Heart Association) | **Published:** 2026-09-03 - **Detail Markdown URL:** [Framework for Assessing Cardiovascular Risk and Fitness for Duty in Tactical Athletes](https://medichelpline.com/clinical-feed/aha-news-0-new-guidance-introduces-framework-for-assessing-cardiovascular-risk-and-fitness.md) > **Executive GIST:** - A new joint American College of Cardiology/American Heart Association Scientific Statement offers the first comprehensive guidance for clinicians caring for **tactical athletes**, a group that includes military personnel, firefighters, law enforcement, emergency medical responders, astronauts and pilots. - The statement introduces the **Tactical Clinical Management (TCM)** framework to integrate evidence-based cardiovascular care with occupational demands, mission requirements and public safety considerations. - Tactical athletes face unpredictable strenuous activity, heavy gear, extreme temperatures, altitude, aviation and diving exposures, and intense psychological stressors that increase cardiac workload and risk. - More than 4 million Americans are estimated to serve as tactical athletes; their service often spans decades and includes older ages of participation compared with competitive athletes. - Traditional cardiovascular risk factors (hypertension, hyperlipidemia, obesity, Type 2 diabetes, smoking) remain common in tactical athletes and should be addressed. - Key recommendations: use the TCM framework; perform preparticipation screening including history and physical; obtain an **ECG** for tactical athletes under 40 exposed to significant cardiovascular strain or in mission-critical roles; consider ECG reasonable for other tactical athletes. - Fitness-for-duty decisions should balance individual health with potential risks to teammates, mission success and public safety. - Cardiovascular implications of cardiomyopathies, arrhythmias, congenital heart disease, coronary artery disease, valvular disease, myocarditis and anticoagulation status require attention and ongoing monitoring. - Operational and environmental considerations — heat, dehydration, altitude, diving, aviation, collision risk and access to emergency medical care — must inform assessment and clearance decisions. - Organizations are advised to maintain **Emergency Action Plans** and rapid **AED** access because screening cannot prevent all sudden cardiac arrests. - The authors call for additional research: creation of registries, improved screening strategies and cardiovascular risk prediction models tailored to tactical athletes. - The statement was published simultaneously in JACC and Circulation on Sept. 3, 2026, and represents a multidisciplinary effort led by clinicians and experts across tactical disciplines. ### 14. [American Heart Association Names Three New Members to Bay Area Board of Directors](https://medichelpline.com/clinical-feed/aha-news-2-bay-area-welcomes-three-new-members-to-board-of-directors.md) - **Source:** AHA News (American Heart Association) | **Published:** 2026-09-03 - **Detail Markdown URL:** [American Heart Association Names Three New Members to Bay Area Board of Directors](https://medichelpline.com/clinical-feed/aha-news-2-bay-area-welcomes-three-new-members-to-board-of-directors.md) > **Executive GIST:** - The American Heart Association announced its incoming **Bay Area** board of directors for the 2026–27 fiscal year, a volunteer group of 12 leaders from healthcare, business and community sectors who will guide local efforts to improve heart and brain health. - The announcement notes the projected rise in burden, citing cardiovascular disease expected to affect more than 6 in 10 U.S. adults by 2050, underscoring the board's role in prevention, education and access to care across the Bay Area. - Leadership for the board includes President **Fatima Rodriguez**, M.D., M.P.H., FACC, FAHA, FASPC; Chair **Jacqueline Shreibati**, M.D., M.S., FACC; Giving Societies Ambassador **Sean Wu**, M.D., Ph.D.; and Leadership Development Chair **Stella Low**. - Three new board members were added: **Taylor Ahlgren**, a product leader, patient advocate and founder focused on healthcare and technology with lived experience of genetic dilated cardiomyopathy; **Lise Luttgens**, a retired nonprofit and healthcare executive with more than 40 years of leadership across governance, fundraising and organizational transformation; and **David Ouyan, M.D.**, a cardiologist, physician-scientist and healthcare AI leader involved in research contributing to FDA-cleared AI technologies and advances in cardiac imaging. - The full 2026–27 Bay Area board roster includes clinicians, executives and nonprofit leaders: Taylor Ahlgren; Robert Chatwani; Maarten Lansberg, M.D., Ph.D.; Justin C. Lee, M.D., FACC; Lise Luttgens; John Maa, M.D.; Henry Nutt; Kristin L. O’Carroll; David Ouyan, M.D.; Nicole Rosendale, M.D.; David B. Vliet, M.B.A.; and Melissa Welch, M.D., M.P.H. - The release directs readers to heart.org/NorthernCalifornia for information on prevention, volunteer opportunities and local support, and provides media and public inquiry contacts. - The announcement reiterates the AHA's mission: funding research, advocating for public health, and providing resources to save and improve lives affected by cardiovascular disease and stroke; it also notes organizational scale (more than 35 million volunteers globally and more than 100 years of health information leadership). ### 15. [Time and frequency characteristics of noninvasive heartbeat sensors: ECG, PCG, SCG, PPG, PiPG](https://medichelpline.com/clinical-feed/plos-one-0-time-and-frequency-characteristics-of-various-noninvasive-heartbeat-sensors.md) - **Source:** PLOS ONE (Medicine) | **Published:** 2026-09-03 - **Detail Markdown URL:** [Time and frequency characteristics of noninvasive heartbeat sensors: ECG, PCG, SCG, PPG, PiPG](https://medichelpline.com/clinical-feed/plos-one-0-time-and-frequency-characteristics-of-various-noninvasive-heartbeat-sensors.md) > **Executive GIST:** - This simultaneous, synchronized study recorded **ECG**, **PCG**, **SCG**, **PPG**, and **PiPG** at 1000 Hz in resting human subjects to produce a unified comparative reference for time- and frequency-domain features. - The acquisition used a custom system with surface Ag/AgCl electrodes for ECG, an electret microphone for PCG, a high-resolution accelerometer (Z-axis) for SCG, a piezoelectric finger sensor for PiPG, and a reflective fingertip PPG (infrared) sensor. - Signals were aligned on the ECG R-peak to compare temporal latencies and morphology across modalities, minimizing inter-system bias by using identical hardware and simultaneous recording. - Findings show reproducible waveform morphology and stable spectral content for **ECG**, **PPG**, and **PiPG**, while **PCG** and **SCG** exhibited higher variability attributed to sensor coupling and anatomical factors. - Temporal latencies relative to the ECG matched expected physiological conduction and mechanical delays; these latency maps can guide multimodal feature alignment and fusion. - Frequency-domain analysis identified modality-specific dominant bands: approximately 30 Hz for PCG, 11–14 Hz for SCG, and 1–2 Hz for PPG and PiPG; bandwidths differ markedly across modalities, reflecting spectral richness. - The study provides practical recommendations for filtering and feature extraction by exporting temporal and spectral content into a single comparative framework rather than validating hardware per se. - A minimal dataset is provided as supporting information (Supporting_Information_file.xlsx), intended as a benchmark for signal-processing, multimodal integration, and wearable cardiac monitoring system design. - The work emphasizes the suitability of these five noninvasive signals for ambulatory monitoring given low-power, compact sensors, and highlights limits of more complex modalities that remain confined to specialized clinical settings. ### 16. [Real-World Evaluation of Mavacamten Safety and Effectiveness in Iranian Hypertrophic Obstructive C](https://medichelpline.com/clinical-feed/bmj-open-7-prospective-evaluation-of-real-world-safety-symptoms-improvement-and-adherence.md) - **Source:** BMJ Open | **Published:** 2026-09-03 - **Detail Markdown URL:** [Real-World Evaluation of Mavacamten Safety and Effectiveness in Iranian Hypertrophic Obstructive C](https://medichelpline.com/clinical-feed/bmj-open-7-prospective-evaluation-of-real-world-safety-symptoms-improvement-and-adherence.md) > **Executive GIST:** - Hypertrophic obstructive cardiomyopathy (HOCM) affects about 70% of individuals with hypertrophic cardiomyopathy, a genetic cardiovascular disorder. - Mavacamten, a cardiac myosin inhibitor, has shown efficacy in reducing left ventricular outflow tract (LVOT) gradients and improving symptoms in randomized trials for HOCM. - Prospective real-world safety and effectiveness data on mavacamten, especially outside Western populations, remain limited. - The PERSIA-HOCM study is a multicentre observational study in Iran enrolling symptomatic HOCM patients (NYHA class II-IV, LVOT gradient ≥50 mm Hg) prescribed mavacamten. - Exclusions include left ventricular ejection fraction under 55%, non-obstructive phenotypes, and lack of consent. - Participants are followed for 1 year at 4-week intervals with echocardiographic evaluations at multiple timepoints. - Data collected include symptoms, NYHA class, vital signs, echocardiographic parameters, dosing, concomitant therapies, and safety events such as mortality and hospitalizations. - Cardiac biomarkers and quality of life assessments occur at weeks 12 and 48. - Primary endpoints focus on safety, NYHA class changes, LVOT gradients, quality of life, biomarkers, and ejection fraction. - Secondary endpoints assess cardiac MRI measures, peak oxygen uptake, and genotype-related outcomes. - Statistical analysis will use R software with descriptive measures, paired t tests, and McNemar’s test. - Ethical approval was obtained; patient confidentiality and informed consent are ensured. - Findings will be reported biannually and shared at scientific forums and publications. ### 17. [Population Impact of Digital Return of Results for Cardiovascular–Kidney–Metabolic Screening at US](https://medichelpline.com/clinical-feed/medrxiv-14-projected-population-level-impact-of-digital-return-of-results-for.md) - **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-09-03 - **Detail Markdown URL:** [Population Impact of Digital Return of Results for Cardiovascular–Kidney–Metabolic Screening at US](https://medichelpline.com/clinical-feed/medrxiv-14-projected-population-level-impact-of-digital-return-of-results-for.md) > **Executive GIST:** - The study models the population-level benefits of implementing **digital return of results (ROR)** for cardiovascular–kidney–metabolic (**CKM**) screening among blood donors in the US using a Monte Carlo simulation (100,000 iterations). - The simulation estimates incident events averted among donors in CKM Stages 1–2 for three outcomes: major adverse cardiovascular events (**MACE**), end-stage renal disease (**ESRD**), and type 2 diabetes (**T2DM**). - The estimand counts only events averted because donors acted in response to ROR; action was translated into prevented events via a hazard-based cumulative-incidence difference with each donor counted at most once. - Eighteen design cells were evaluated: donor volumes of 300,000, 1 million, and 8 million per year; horizons of 5 and 10 years; and action-rate gains of +10, +20, and +30 percentage points (pp). A complementary two-arm simulation estimated assurance (expected power) for detecting effects in a single deployment. - Under the primary scenario (+20 pp action-rate gain), ROR at a single large center (300,000 donors/year) prevented a median 2,201 events (95% UI 1,099–4,364) over 10 years; scaled to 58,526 (29,154–116,769) at the national donor pool (8 million/year). - All 18 design cells had strictly positive 95% lower bounds, indicating projected benefit across scenarios. The number needed to screen (NNS) was 136 and the screening cost per event prevented was $2,045 (assuming $15 per donor), both invariant to donor volume. - Impact scaled linearly with donor volume and effect size but sub-linearly with time horizon. Assurance for detecting effects was ≥99.6% for gains of +20 pp or larger in all cells and >99.9% in all but the smallest 5-year cell. - The authors conclude that even under conservative assumptions, digital CKM ROR at blood donation centers could prevent hundreds to tens of thousands of cardiometabolic events at screening costs within accepted prevention benchmarks, supporting a pragmatic randomized evaluation. - The study used aggregate inputs from published literature and an institutional donor-volume figure; no individual-level human data were used. Code and results are publicly available on GitHub for reproducibility. - Competing interests: ZA reported honoraria and research funding; all other authors declared no competing interests. ### 18. [Sex and NOS inhibition shape distinct cardiac responses to cardiometabolic stress in older mice](https://medichelpline.com/clinical-feed/biorxiv-6-nitric-oxide-synthase-inhibition-and-biological-sex-define-different-cardiac.md) - **Source:** bioRxiv (Biomedical Preprints) | **Published:** 2026-09-03 - **Detail Markdown URL:** [Sex and NOS inhibition shape distinct cardiac responses to cardiometabolic stress in older mice](https://medichelpline.com/clinical-feed/biorxiv-6-nitric-oxide-synthase-inhibition-and-biological-sex-define-different-cardiac.md) > **Executive GIST:** - Preclinical study examined how **biological sex** and graded inhibition of **nitric oxide synthase (NOS)** influence cardiac outcomes in older C57BL/6J mice subjected to cardiometabolic stress (high-fat diet, HFD). - Older male and female mice (>24 weeks) received HFD plus either low-dose or high-dose NOS inhibition using N(ω)-nitro-L-arginine methyl ester (**L-NAME**) for 15 weeks; low-dose L-NAME (0.3 g/L) was used only in females, high-dose (0.5 g/L) in both sexes. - Female mice given low-dose L-NAME+HFD developed a **HFpEF-like** phenotype: impaired diastolic function, exercise intolerance, and preserved systolic function. - Increasing NOS inhibition in females did not further worsen diastolic dysfunction but triggered activation of inflammatory and cellular stress transcriptional pathways in the heart. - Male mice receiving high-dose L-NAME+HFD developed hypertension, elevated ventricular pressures and reduced systolic function consistent with a **HFrEF-like** phenotype. - Despite divergent functional phenotypes between sexes, circulating lipidomic profiling showed broadly conserved remodeling of **sphingolipid** and **phospholipid** classes, with sex-specific alterations in phosphatidylinositol and lysophosphatidylcholine species. - Transcriptomic analyses found shared regulation across sexes of extracellular matrix, calcium-handling and metabolic pathways; greater NOS inhibition associated with transcriptional signatures of inflammatory signaling, cellular stress responses and mitochondrial homeostasis. - Authors conclude that cardiometabolic stress yields multiple possible cardiac remodeling trajectories rather than a single HF phenotype, and that sex and NOS inhibition dose direct distinct functional and molecular outcomes. - No competing interests were declared by the authors in the source document. ### 19. [Worth-a-Taste Wednesday: AHA launches nutrition program for Springdale seniors](https://medichelpline.com/clinical-feed/aha-news-0-worth-a-taste-wednesday-brings-new-opportunities-for-better-nutrition-to.md) - **Source:** AHA News (American Heart Association) | **Published:** 2026-09-02 - **Detail Markdown URL:** [Worth-a-Taste Wednesday: AHA launches nutrition program for Springdale seniors](https://medichelpline.com/clinical-feed/aha-news-0-worth-a-taste-wednesday-brings-new-opportunities-for-better-nutrition-to.md) > **Executive GIST:** - The American Heart Association (AHA) launched **Worth-a-Taste Wednesday**, a new nutrition education and food access initiative, at the Springdale Senior Center on Sept. 2, 2026. - The program runs weekly on Wednesdays at 11:15 a.m. through April and is designed for older adults. - It uses a repeated-exposure model to encourage participants to sample fresh, locally grown foods in a group setting. - Goals include increasing confidence trying new produce, overcoming unfamiliarity with fresh foods, and supporting sustainable, heart-healthy behavior change. - The initiative addresses barriers for older adults such as lack of confidence preparing healthy foods and long-established eating habits that can raise risk for heart disease, stroke and other chronic conditions. - Worth-a-Taste Wednesday is a collaboration between AHA-NWA, the Springdale Senior Center and Spring Creek Food Hub, with funding from Walmart for Good. - The program features produce sourced through **Spring Creek Food Hub** to strengthen connections to the local food system. - Participants receive sampling opportunities, practical preparation and shopping tips, peer connection and increased awareness of nutritious local food options. - Beth Jones, community impact director for AHA Northwest Arkansas, emphasized meeting people where they are and creating joyful food experiences to support small changes that improve health and quality of life. - For more information, the contact listed is Beth.Jones@heart.org. - The program aligns with the AHA’s commitment to equitable opportunities for better health and is part of the organization’s community impact work in Northwest Arkansas. ### 20. [Shandy Belford Leads Oklahoma City Go Red for Women Campaign to Advance Heart Health](https://medichelpline.com/clinical-feed/aha-news-1-oklahoma-city-area-bank-executive-spearheads-women-s-heart-health-movement.md) - **Source:** AHA News (American Heart Association) | **Published:** 2026-09-02 - **Detail Markdown URL:** [Shandy Belford Leads Oklahoma City Go Red for Women Campaign to Advance Heart Health](https://medichelpline.com/clinical-feed/aha-news-1-oklahoma-city-area-bank-executive-spearheads-women-s-heart-health-movement.md) > **Executive GIST:** - The American Heart Association-OKC named Shandy Belford, CEO of Arvest Bank’s central Oklahoma market, as chair of the 2026 Oklahoma City **Go Red for Women** movement. - Belford will lead efforts to empower women to prioritize heart health, increase awareness, and close gaps in cardiovascular care, education and research. - The campaign will culminate in the 2026 Go Red for Women Luncheon on Nov. 6, 11 a.m.–1 p.m., at the Meinders Hall of Mirrors, Civic Center Music Hall. - Belford cites personal family experience with heart disease and emphasizes prevention, early detection and routine screening as lifesaving measures. - Less than half of women are aware of their cardiovascular disease risk; the movement aims to improve knowledge of personal health numbers and risk factors. - Belford plans to engage community leaders, businesses and advocates throughout the campaign to discuss prevention and access to care. - Jill VanEgmond, executive director of AHA-OKC, praised Belford’s dedication to the movement. - The local luncheon is nationally sponsored by CVS Health and supported locally by OU Health; the AHA provided contact information for media and public inquiries. - The press release reiterates the American Heart Association’s mission and summarizes the Go Red for Women initiative, including the statistic that cardiovascular disease claims the lives of **1 in 3 women**. - For more information, the release lists Sydney Ore as a contact and provides URLs for event and organizational resources. ### 21. [Shingrix shingles vaccine associated with 9% lower cardiovascular burden over 7 years](https://medichelpline.com/clinical-feed/medical-news-today-0-shingles-vaccine-linked-to-9-lower-cardiovascular-burden-in-new-study.md) - **Source:** Medical News Today | **Published:** 2026-09-02 - **Detail Markdown URL:** [Shingrix shingles vaccine associated with 9% lower cardiovascular burden over 7 years](https://medichelpline.com/clinical-feed/medical-news-today-0-shingles-vaccine-linked-to-9-lower-cardiovascular-burden-in-new-study.md) > **Executive GIST:** - A new observational analysis published in Nature Medicine examined electronic health records from the USA TriNetX network to compare cardiovascular outcomes after shingles vaccination. The cohort included 72,920 people aged 60 and older: 36,460 who received the recombinant zoster vaccine **Shingrix** and an equal number who had received the live-virus vaccine Zostavax. - Researchers measured cardiovascular disease burden over seven years after vaccination and found a **9% reduction in cardiovascular burden** among people who received Shingrix compared with those who received Zostavax. - Secondary findings included a **12% lower burden of heart failure**, a **10% lower burden of ischemic heart disease**, a **12% reduction in stroke burden among men**, and a **7% lower burden of atrial fibrillation** for both sexes in the Shingrix group. - Investigators and commentators emphasized the public health relevance because cardiovascular disease remains the leading cause of death worldwide; even modest relative reductions could have large population effects. - The study is observational. Authors and interviewed clinicians noted that randomized clinical trials are needed to confirm causality; the article states two randomized trials are already underway and mechanistic studies are required. - Possible mechanisms discussed include prevention of shingles and its associated inflammatory response, and immunologic effects related to the vaccine adjuvant **AS01**; the vaccine may influence inflammatory pathways such as **interleukin-6 (IL-6)** and produce longer-lasting immune changes. - Experts quoted (Max Taquet, PhD; Heather Johnson, MD; Kevin Shah, MD; Renato Apolito, MD) endorsed the study as intriguing and potentially clinically meaningful but cautioned that results do not prove cause and effect and require confirmation. - The FDA approved the recombinant zoster vaccine Shingrix in 2017; CDC recommends two doses for adults aged 50 and older to prevent shingles. Prior studies have suggested associations between Shingrix and reduced risks of dementia and cardiovascular disease, and this new analysis adds further observational evidence. - The report notes that Shingrix’s established role in preventing shingles and its complications remains a primary reason for vaccination and that potential cardiovascular benefits could provide an additional rationale for uptake if confirmed. ### 22. [Two-time sudden cardiac arrest survivor to speak at 2026 Pittsburgh Heart Walk](https://medichelpline.com/clinical-feed/aha-news-0-twice-saved-from-sudden-cardiac-arrest-local-woman-to-share-lifesaving-story-at.md) - **Source:** AHA News (American Heart Association) | **Published:** 2026-09-02 - **Detail Markdown URL:** [Two-time sudden cardiac arrest survivor to speak at 2026 Pittsburgh Heart Walk](https://medichelpline.com/clinical-feed/aha-news-0-twice-saved-from-sudden-cardiac-arrest-local-woman-to-share-lifesaving-story-at.md) > **Executive GIST:** - Yvonne English Roebuck, EdD, survived two episodes of **sudden cardiac arrest**: the first in 2015 at a party and a second eight years later. - At the 2015 event a nurse immediately provided **CPR** and first responders used an **AED** to deliver three shocks that restored her heartbeat. - During her second arrest an **implantable cardioverter defibrillator (ICD)** delivered a lifesaving shock after she had initially been reluctant to receive the device following her first arrest. - Roebuck emphasizes the lifesaving impact of immediate **bystander CPR**, accessible **AEDs**, and preparedness during cardiac emergencies. - The American Heart Association notes that nearly 90% of people who experience cardiac arrest outside a hospital do not survive, and that immediate CPR can double or triple survival chances. - Roebuck will speak at the **2026 Pittsburgh Heart Walk** on Saturday, Sept. 12, at Point State Park to raise awareness about cardiovascular health and CPR training. - The Pittsburgh Heart Walk supports the AHA’s mission through fundraising, community education, corporate engagement, CPR education access and research funding. - Registration and Hands-Only CPR resources are available at www.Heart.org/PittsburghWalk. - Roebuck credited the American Heart Association for education and support and said she is grateful to those who acted to save her life. - Media contact information was provided in the source for Karen Colbert with phone and email details, and the AHA background and mission information was included. ### 23. [Mark Garrett Leads AHA Heart of Kansas City Campaign to Improve Community Health](https://medichelpline.com/clinical-feed/aha-news-1-people-first-executive-drives-community-effort-to-improve-health-in-kansas-city.md) - **Source:** AHA News (American Heart Association) | **Published:** 2026-09-02 - **Detail Markdown URL:** [Mark Garrett Leads AHA Heart of Kansas City Campaign to Improve Community Health](https://medichelpline.com/clinical-feed/aha-news-1-people-first-executive-drives-community-effort-to-improve-health-in-kansas-city.md) > **Executive GIST:** - Mark Garrett, Chief People Officer at Garney, is volunteer chair of the American Heart Association’s **Heart of Kansas City** campaign, leading efforts to promote healthier lives across Kansas City. - The campaign mobilizes companies, community leaders and individuals to advance the AHA’s Four Chambers: **discovery**, **advocacy**, **access** and **knowledge**. - Garrett’s personal connection to heart health and prior senior leadership roles at Blue Cross and Blue Shield of Kansas City, Smithfield Foods, Kansas City Public Schools and Hallmark motivate his involvement. - Garrett serves on multiple local boards, including the YMCA of Greater Kansas City and the Kansas City Sports Commission, and has a record of prior board service with civic and charitable organizations. - Carla Duyree, volunteer board chair of AHA – Kansas City, praised Garrett’s vision and commitment as reasons he is an outstanding campaign chair. - The campaign will culminate in the 2027 Kansas City Heart Ball on February 27 at The Loews Kansas City Hotel, a fundraising and recognition event that includes survivor stories, honors, dinner, dancing and an auction. - Major sponsors for the Heart Ball include Garney, JE Dunn Construction and Lockton, among other local companies committed to community health. - For more information or to support/attend the Kansas City Heart Ball, the source directs readers to www.heart.org/kcheartball or to contact Jackie McMahon at Jackie.McMahon@heart.org. - The American Heart Association is described as a long-standing organization dedicated to equitable health, funding research, advocating for public health and providing resources to address cardiovascular disease and stroke. - Media contact listed is DeEtta Lee, Sr. Communications Director, with email DeEtta.Lee@heart.org and phone 515-250-8392; public inquiries number is 1-800-AHA-USA1. ### 24. [Kids Heart Challenge and American Heart Challenge teach lifesaving skills in Savannah schools](https://medichelpline.com/clinical-feed/aha-news-0-kids-heart-challenge-american-heart-challenge-equip-savannah-area-students-with.md) - **Source:** AHA News (American Heart Association) | **Published:** 2026-09-02 - **Detail Markdown URL:** [Kids Heart Challenge and American Heart Challenge teach lifesaving skills in Savannah schools](https://medichelpline.com/clinical-feed/aha-news-0-kids-heart-challenge-american-heart-challenge-equip-savannah-area-students-with.md) > **Executive GIST:** - The American Heart Association’s **Kids Heart Challenge** and **American Heart Challenge** reached more than **17,000** students across Chatham County during the 2025–26 school year, delivered through 26 participating district schools. - Programs taught how to call **911**, perform **Hands-Only CPR**, and recognize stroke warning signs using **B.E. F.A.S.T**, and promoted heart-healthy behaviors. - Participating schools raised over **$75,000** to support the American Heart Association’s mission. - National context: more than **350,000** out-of-hospital cardiac arrests occur in the U.S. annually, with approximately **23,000** affecting children; bystanders are often the first link in the chain of survival. - Since 2021, the two school-based initiatives have reached more than **1.1 million** students, families, and educators nationwide. - Local implementation examples: Curwin Reese, a physical education teacher at The Early Learning Center at Henderson E. Formey School, integrates the program into a fitness unit; the curriculum reinforces physical activity, nutrition, sleep, and avoidance of vaping and tobacco. - Personal story: Dmitri, born with a congenital heart defect who had open-heart surgery at age 5, shares his experience with classmates to raise awareness and inspire peers. - Program resources for schools include CPR in Schools kits, physical and mental well-being grants, professional development, cash awards, and other educational supports. - A list of Savannah/Chatham County schools signed up for the 2026–27 school year is provided and schools are invited to register at heart.org/jointhechallenge. - Contact and organizational background: the release includes AHA media and public inquiry contacts and summarizes the AHA’s mission and scope of work. ### 25. [Optimal DAPT Duration After PCI with Contemporary DES: Network Meta-analysis of RCTs](https://medichelpline.com/clinical-feed/plos-one-7-dual-antiplatelet-therapy-duration-after-percutaneous-coronary-intervention.md) - **Source:** PLOS ONE (Medicine) | **Published:** 2026-09-02 - **Detail Markdown URL:** [Optimal DAPT Duration After PCI with Contemporary DES: Network Meta-analysis of RCTs](https://medichelpline.com/clinical-feed/plos-one-7-dual-antiplatelet-therapy-duration-after-percutaneous-coronary-intervention.md) > **Executive GIST:** - This network meta-analysis pooled 28 randomized trials including 84,325 patients undergoing percutaneous coronary intervention (PCI) with second- or third-generation **drug-eluting stents (DES)** to compare abbreviated (<12 months), 12-month, and extended DAPT durations. - The systematic search covered PubMed, Embase, and Scopus from January 2008 through March 21, 2026; the protocol was prospectively registered on PROSPERO (CRD420261349664). - Primary efficacy and safety endpoints were trial-defined **major adverse cardiovascular events (MACE)** and **major bleeding**, respectively. - Relative effects were estimated by frequentist network meta-analysis using multivariate random-effects models; treatment ranking used SUCRA values. - Compared with 12-month DAPT, 1-, 3-, and 6-month strategies showed no significant difference in MACE: 1-month RR 1.03 (95% CI 0.88–1.22); 3-month RR 0.95 (95% CI 0.82–1.10); 6-month RR 1.06 (95% CI 0.88–1.27). - Shorter regimens were associated with significantly lower major bleeding: 1-month RR 0.59 (95% CI 0.42–0.82); 3-month RR 0.64 (95% CI 0.49–0.84); 6-month RR trended lower RR 0.68 (95% CI 0.46–1.00). - SUCRA rankings favored the **3-month DAPT** strategy for lowest ischemic risk (MACE) and the **1-month DAPT** strategy for lowest bleeding risk, with the 3-month regimen showing the most favorable overall profile across analyses. - Authors conclude that abbreviated DAPT (1–3 months) reduces bleeding without evidence of increased ischemic events versus 12 months, and propose 3 months as a pragmatic threshold, while cautioning interpretation due to study-level network meta-analysis limitations and lack of statistically significant efficacy differences. - Risk-of-bias, inconsistency, publication bias, and certainty of evidence were assessed using Cochrane RoB2, inconsistency tests, funnel plots/Egger-type tests, and GRADE, respectively; specific domain ratings and detailed trial-level data are reported in the manuscript and supporting information. ### 26. [ECG-based longitudinal risk prediction with ECG-RISK across organ systems](https://medichelpline.com/clinical-feed/medrxiv-20-ecg-based-longitudinal-risk-prediction-across-diseases-and-organ-systems.md) - **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-09-02 - **Detail Markdown URL:** [ECG-based longitudinal risk prediction with ECG-RISK across organ systems](https://medichelpline.com/clinical-feed/medrxiv-20-ecg-based-longitudinal-risk-prediction-across-diseases-and-organ-systems.md) > **Executive GIST:** - The study developed **ECG-RISK**, a multitask survival model using ECG waveforms, demographics, and routine laboratory data to predict 67 incident three-character ICD-10 endpoints in a longitudinal fashion. - The model was trained and evaluated on 86,673 patients from the MIMIC-IV database and used routinely available inputs from clinical care. - Overall discrimination at the organ level was highest for **heart**, **brain**, **kidney**, and **lung** endpoints, with organ-level C-indices reported between 0.796 and 0.825. - Some organ systems, notably the **liver** and **pancreas**, showed lower predictive discrimination compared with cardiovascular, neurological, renal, and pulmonary endpoints. - An **ECG-only** version of the model achieved strong discrimination across most endpoints, indicating rich prognostic signal in ECG waveforms alone. - Adding laboratory data and ECG inputs on top of demographic information produced variable incremental improvements depending on the endpoint. - For nine exploratory aggregated outcomes, Kaplan–Meier curves for model-score tertiles showed clear separation; discrimination was highest for **dementia** (C-index 0.891) and **heart failure** (C-index 0.857). - The authors note that external validation and competing-risk analyses remain necessary to determine generalisability and clinical utility. - Data provenance: analyses performed on de-identified MIMIC-IV, MIMIC-IV-ED and MIMIC-IV-ECG datasets accessed via PhysioNet; raw patient-level data cannot be redistributed by the authors. - Ethical oversight: use of MIMIC-IV data was approved by the Beth Israel Deaconess Medical Center IRB with a waiver of individual informed consent; the study was a secondary analysis of de-identified data. ### 27. [Stepwise DAPT de-escalation vs standard DAPT after drug-coated balloon angioplasty in multivessel](https://medichelpline.com/clinical-feed/medrxiv-15-impact-of-stepwise-dual-antiplatelet-therapy-de-escalation-in-patients-with.md) - **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-09-02 - **Detail Markdown URL:** [Stepwise DAPT de-escalation vs standard DAPT after drug-coated balloon angioplasty in multivessel](https://medichelpline.com/clinical-feed/medrxiv-15-impact-of-stepwise-dual-antiplatelet-therapy-de-escalation-in-patients-with.md) > **Executive GIST:** - This prespecified subgroup analysis of the REC-CAGEFREE II trial assessed outcomes after **drug-coated balloon (DCB)**–only angioplasty in patients with acute coronary syndrome (ACS) who received either stepwise **dual antiplatelet therapy (DAPT)** de-escalation or standard DAPT. - The trial randomized 1,948 exclusively DCB-treated ACS participants across 41 sites in China to stepwise DAPT de-escalation or standard DAPT; this analysis stratified patients by angiographic vessel status (multivessel versus single-vessel disease). - Multivessel disease was present in 720 of 1,948 patients (37.0%). - The primary endpoint was net adverse clinical events (NACE) at 12 months, defined as a composite of all-cause death, stroke, myocardial infarction, revascularization, and BARC type 3 or 5 bleeding. - Patients with **multivessel disease** had a higher 12‑month NACE rate than those with single‑vessel disease (12.5% vs 6.7%); inverse probability of treatment weighting (IPTW) hazard ratio 1.84 (95% CI 1.35–2.51), P < 0.001. - There was no statistically significant interaction between vessel status (multivessel vs single‑vessel) and treatment allocation for NACE (Pinteraction = 0.542), indicating similar relative effects of the two DAPT strategies across subgroups. - In the multivessel subgroup, NACE occurred in 44/368 (12.1%) with stepwise de-escalation and 45/352 (12.9%) with standard DAPT (HR IPTW 0.95, 95% CI 0.62–1.75, P = 0.818). - In the single‑vessel subgroup, NACE occurred in 43/607 (7.1%) with stepwise de‑escalation and 39/621 (6.3%) with standard DAPT (HR IPTW 1.12, 95% CI 0.72–1.70, P = 0.611). - For a prespecified hierarchical secondary endpoint, win-ratio analyses favored stepwise de-escalation in both multivessel and single-vessel subgroups. - Overall conclusion: among ACS patients treated with DCB-only angioplasty, multivessel disease carried higher absolute NACE risk, and stepwise DAPT de-escalation and standard DAPT showed similar risk–benefit profiles in both vessel-status subgroups. - Trial registration: ClinicalTrials.gov NCT04971356. Data availability: available from corresponding author on reasonable request. Ethical approval and informed consent were obtained; details reported in the source. ### 28. [Cost, Outcomes, and Value Variation in Percutaneous Mechanical Circulatory Support: National Analy](https://medichelpline.com/clinical-feed/medrxiv-15-cost-outcome-variation-in-percutaneous-mechanical-circulatory-support-a.md) - **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-09-02 - **Detail Markdown URL:** [Cost, Outcomes, and Value Variation in Percutaneous Mechanical Circulatory Support: National Analy](https://medichelpline.com/clinical-feed/medrxiv-15-cost-outcome-variation-in-percutaneous-mechanical-circulatory-support-a.md) > **Executive GIST:** - This retrospective cohort study used the National Inpatient Sample to evaluate national variation in utilization, outcomes, and costs for percutaneous mechanical circulatory support (pMCS) in non-elective critically ill hospitalizations. - The analysis compared two pMCS strategies identified by ICD-10 codes: **intra-aortic balloon pump (IABP)** and **percutaneous left ventricular assist device (pLVAD)**. - A total of 57,910 weighted hospitalizations were included: 78% IABP and 22% pLVAD. - In-hospital mortality exceeded 30% across regions despite risk adjustment; both strategies showed observed-to-expected (O/E) mortality ratios of 0.92, indicating outcomes better than expected after adjustment. - Mean hospital charges were higher for **pLVAD** than **IABP** ($403,731 vs $320,769). - Costs were higher than expected for both devices, with IABP demonstrating greater relative cost inflation (O/E 1.41) and pLVAD associated with higher absolute cost. - Significant regional variation was observed: the West had the highest costs and the Midwest the lowest (p < 0.001). - A value-of-care framework integrating risk-adjusted outcomes and expenditures indicated that **IABP** was associated with lower cost and comparable outcomes, while **pLVAD** incurred higher cost without proportional outcome improvement. - The authors declared no competing interests; ethical approvals and participant consent statements were reported as obtained. Data are available on reasonable request to the authors. ### 29. [SERVE OC RCT: Family-Based, Community Intervention for Cardiovascular Health in Latino and Vietnam](https://medichelpline.com/clinical-feed/medrxiv-12-a-randomized-controlled-trial-evaluating-a-community-based-family-network-heart.md) - **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-09-02 - **Detail Markdown URL:** [SERVE OC RCT: Family-Based, Community Intervention for Cardiovascular Health in Latino and Vietnam](https://medichelpline.com/clinical-feed/medrxiv-12-a-randomized-controlled-trial-evaluating-a-community-based-family-network-heart.md) > **Executive GIST:** - The SERVE OC trial is a community-engaged, two-arm randomized controlled trial testing a family-based heart health intervention versus individual self-management in underserved populations. - The study enrolled 190 families (486 individuals) of Latino and Vietnamese background and obtained baseline measures spanning demographics, AHA **Life's Essential 8** (LE8), psychosocial factors, food security, and social determinants of health (SDOH). - Primary outcomes are achievement of ideal **cardiovascular health** per LE8 and change in **systolic blood pressure** measured at 12, 24, and 36 months. - At baseline, more than 83% of participants had suboptimal LE8 scores; average adult total LE8 score was 66.61 ± 11.96 and average child LE8 score was 76.52 ± 10.15. - Physical activity was identified as the weakest LE8 domain among adults at baseline. - Analyses found that greater SDOH burden and food security were associated with significantly lower odds of ideal CVH and lower LE8 scores respectively, indicating links between social determinants, food measures, and CVH. - The trial demonstrates feasibility of recruiting families into a culturally tailored, multilevel intervention targeted at CVD disparities and highlights substantial baseline CVD risk and SDOH burden in the cohort. - The protocol and baseline data are intended to inform scalable, family-focused prevention strategies across the life course; the trial is registered (NCT05641519) and had IRB approval from University of California, Irvine. - Data, analytic methods, and study materials are available from the corresponding author upon reasonable request. The report is a preprint and has not been peer reviewed. ### 30. [Sex Differences in Allosensitization and Heart Transplant Access in Adults with Congenital Heart D](https://medichelpline.com/clinical-feed/medrxiv-0-sex-differences-in-the-impact-of-allosensitization-on-waitlist-access-and-post.md) - **Source:** medRxiv (Clinical Preprints) | **Published:** 2026-09-02 - **Detail Markdown URL:** [Sex Differences in Allosensitization and Heart Transplant Access in Adults with Congenital Heart D](https://medichelpline.com/clinical-feed/medrxiv-0-sex-differences-in-the-impact-of-allosensitization-on-waitlist-access-and-post.md) > **Executive GIST:** - This retrospective OPTN/UNOS analysis evaluated first-time heart transplant (HT) candidates with adult congenital heart disease (**ACHD**) listed from 2018–2025. Sensitization was defined by calculated panel reactive antibodies (**cPRA**) at listing, with high sensitization as cPRA >50%. - The cohort included 856 candidates; 38% were female. Females were more likely to be highly sensitized than males (23% vs 14%); age-adjusted odds ratio (OR) 1.81 (95% CI 1.26–2.61). The female excess in sensitization persisted after adjustment for surgical burden. - Sensitization reduced **transplant access** for females but not males. Among females, the proportion transplanted fell from 84% (non-sensitized) to 71% (sensitized) and median wait increased from 60 to 110 days (p < 0.001). In males, transplant proportions were 79% for both sensitized and non-sensitized with median waits of 88 vs 98 days. - In Fine-Gray competing-risks models adjusted for age at listing, mechanical support at listing, and number of prior cardiac surgery categories, sensitized females had a lower subdistribution hazard for transplant (sHR 0.54, 95% CI 0.41–0.72). Sensitization had no effect in males (sHR 0.96, 95% CI 0.73–1.26). The sex × sensitization interaction was significant (interaction sHR 0.64, 95% CI 0.44–0.94; p = 0.02). - Post-transplant, mortality was numerically higher in sensitized versus non-sensitized candidates in both sexes, but the sex × sensitization interaction on 1-year mortality was not statistically significant. - The sex-asymmetric effect of allosensitization on transplant access was more pronounced among multiorgan candidates. The exposures responsible for the female excess in sensitization were not defined in the registry data. - Analyses and conclusions are limited to registry data; details on non-surgical alloantigen exposures were not reported. The study was IRB-approved (STU-2023-0713) and funded by NIH (K23HL171828) and AHA (23CDA1050881). ## Machine-Readable Pagination & Traversal - [← Main Clinical Feed Hub](https://medichelpline.com/clinical-feed.md) - [Next Page (Page 2) →](https://medichelpline.com/clinical-feed/cardiology.md?page=2) ## Other Clinical Specialties - [Critical Care](https://medichelpline.com/clinical-feed/critical-care.md) - [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md) - [Oncology](https://medichelpline.com/clinical-feed/oncology.md) - [Neurology](https://medichelpline.com/clinical-feed/neurology.md) - [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md) - [Research Highlights](https://medichelpline.com/clinical-feed/research-highlights.md) - [Dentistry](https://medichelpline.com/clinical-feed/dentistry.md) - [Public Health](https://medichelpline.com/clinical-feed/public-health.md) - [Regulatory & FDA](https://medichelpline.com/clinical-feed/regulatory.md) - [Research & Trials](https://medichelpline.com/clinical-feed/research.md) ## Medical & Regulatory Disclaimer > [!CAUTION] > MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations. > Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.